- Home
- STXS vs CHRS Comparison
STXS vs CHRS Comparison
Compare STXS & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STXS
- CHRS
- Stock Information
- Founded
- STXS 1990
- CHRS 2010
- Country
- STXS United States
- CHRS United States
- Employees
- STXS N/A
- CHRS N/A
- Industry
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STXS Health Care
- CHRS Health Care
- Exchange
- STXS Nasdaq
- CHRS Nasdaq
- Market Cap
- STXS N/A
- CHRS 191.3M
- IPO Year
- STXS 2004
- CHRS 2014
- Fundamental
- Price
- STXS $2.08
- CHRS $1.39
- Analyst Decision
- STXS Strong Buy
- CHRS Strong Buy
- Analyst Count
- STXS 2
- CHRS 4
- Target Price
- STXS $4.50
- CHRS $5.38
- AVG Volume (30 Days)
- STXS 386.4K
- CHRS 2.0M
- Earning Date
- STXS 03-03-2025
- CHRS 03-12-2025
- Dividend Yield
- STXS N/A
- CHRS N/A
- EPS Growth
- STXS N/A
- CHRS N/A
- EPS
- STXS N/A
- CHRS N/A
- Revenue
- STXS $25,143,000.00
- CHRS $304,340,000.00
- Revenue This Year
- STXS $3.73
- CHRS $2.47
- Revenue Next Year
- STXS $54.27
- CHRS N/A
- P/E Ratio
- STXS N/A
- CHRS N/A
- Revenue Growth
- STXS N/A
- CHRS 44.19
- 52 Week Low
- STXS $1.66
- CHRS $0.66
- 52 Week High
- STXS $3.29
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- STXS 43.06
- CHRS 45.86
- Support Level
- STXS $2.21
- CHRS $1.38
- Resistance Level
- STXS $2.17
- CHRS $1.60
- Average True Range (ATR)
- STXS 0.15
- CHRS 0.13
- MACD
- STXS -0.04
- CHRS -0.03
- Stochastic Oscillator
- STXS 7.25
- CHRS 9.52
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.